Hybridoma technology described by kohler and Milstein produce only mouse immunoglobulins.
Such immunoglobulins have limited use due to its negative side effects such as the recipientâ€™s
immune response. The production of a non murine monoclonal antibody to combat the problems of
murine monoclonal antibody is again difficult due to the lack of a suitable myeloma cell line.
Heterohybridoma formed by the fusion of lymphocyte of one species with the myeloma cell of a
different species is the solution, which can be used for the production of non murine monoclonal
heterohybridoma, non-murine, lymphocytes, myeloma cell, monoclonal antibodies